Lancet Neurology: Application of methiciltic acid in patients with cerebral hemorrhage (STOP-AUST): A multi-center, randomized, placebo-controlled Phase 2 trial

Globally, 18 million people suffer from the after-effects of cerebral hemorrhage, and 3 million people die each year from the disease, accounting for 5 per cent of all human deaths.
the clinical prognosis of patients with cerebral hemorrhage were age, neurological deficiency, cause of bleeding, bleeding site and amount of bleeding.
, the amount of bleeding is the most important factor.
is ished, cerebral hemorrhage is usually a dynamic process.
is often used to reduce the amount of bleeding in cases such as acute trauma or multiple months.
study was a forward-looking, double-blind, randomized, placebo-controlled Phase 2 trial at 13 stroke centers in Australia, Finland and Taiwan.
if the patient is older than or equal to 18 years of age, he or she suffers from acute cerebral hemorrhage that meets clinical standards (e.g. Glasgow Coma Score 7 points, cerebral hemorrhage volume of 70 ml, no secondary cause of cerebral hemorrhage was found or suspected, no thrombosis events occurred in the past 12 months, no surgery planned for the next 24 hours, and no anticoagulants were used), contrast agent exoduses (so-called speckular signs) appeared in CT angiology, and within 4-5 hours of symptoms and 1 hour after CT angiosis, are eligible for treatment.
patients were randomly assigned (1:1) to receive 1g of intravenous aminocyclic acid 10min within 4.5h of the on-the-look symptoms and another 1g within 8h or to use a matching placebo.
result is an increase in cerebral hemorrhage within 24 hours (33% relative or 6 ml absolute value).
between March 1, 2013 and August 13, 2019, the study randomly assigned 100 participants to the methamphetamine group (n-50) or the placebo group (n-50).
age was 71 years (IQR 57-79) and the average amount of cerebral hemorrhage was 14.6 ml (7.9-32.7).
the main results of the two groups were no different: 26 cases in the placebo group (52%) and 22 cases (44%) in the acetate group showed an increase in cerebral hemorrhage (advantage ratio of 0.72 (OR) (95% CI 0.32-1.59) and p=0.41).
there was no significant difference in the proportion of patients who died or had complications of thrombotic embolism between the two groups: 8 (16%) deaths in the placebo group, 13 deaths (26%) in the methamphetamine group, and 2 cases (4%) and 1 (2%) complications of thrombosis.
all deaths are not thought to be related to the study of drugs.
, although this treatment is safe and does not increase complications of thromboembolism, this study does not provide evidence to prevent the growth of cerebral hemorrhage.
increased bleeding is the main cause of acute cerebral hemorrhage morbidity and mortality, new, safe and effective treatments are urgently needed to prevent persistent bleeding.
Meretoja, Atte et al. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology, Volume 19, Issue 12, 980 - 987MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to reproduce, and any media, website or individual must indicate "Source: Mays Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here